Treatment of extrafoveal lesions

Treatment of extrafoveal lesions

Intravitreal Ranibizumab appears to be more effective than thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularisation secondary to agerelated macular degeneration, according to the results of a retrospective study. In a study involving 24 eyes with the extrafoveal neovascularisations, the mean best corrected visual acuity was significantly better in eyes receiving the anti-VEGF agent than in those undergoing the laser treatment (logMAR 0.16 vs 0.92, p = 0.02) at a mean follow-up of 26 weeks. Moreover, the recurrence rate in the laser group was 84.6 per cent, compared to only 18.2 per cent in the ranibizumab group (p < 0.001).

(Ladas et al, Ophthalmologica 2012; DOI: 10.1159/000337347.)

Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...